NuCana (NCNA) Capital Expenditures (2017 - 2024)
NuCana (NCNA) reported Capital Expenditures of -$1283.5 for Q4 2024, down 112.93% on a YoY basis from $9929.2 in Q1 2024, and down 112.93% sequentially from $9929.2 in Q4 2023.
NuCana (NCNA) Capital Expenditures (2017 - 2024) Analysis & Trends
NuCana (NCNA) has 7 years of Capital Expenditures data on file, last reported at -$1283.5 in Q4 2024.
- For the quarter ending Q4 2024, Capital Expenditures fell 112.93% year-over-year to -$1283.5; the trailing twelve-month figure through Dec 2024 stood at $9912.4 (down 93.26% YoY), and the FY2024 full-year result was -$5113.1, down 202.77% from the prior year.
- Capital Expenditures retreated to -$1283.5 in Q4 2024, from $9929.2 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $938840.7 in Q4 2020 to a low of -$433608.9 in Q3 2020.
- A 4-year average of $52880.3 and a median of -$4966.8 in 2020 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 873.6% in 2020, while the deepest fall reached 4294.97% in 2020.
- Tracing NCNA's Capital Expenditures over 4 years: stood at $938840.7 in 2020, then slumped by 84.64% to $144237.1 in 2021, then plunged by 93.12% to $9929.2 in 2023, then plunged by 112.93% to -$1283.5 in 2024.
- Business Quant data shows NCNA's Capital Expenditures at -$1283.5 in Q4 2024, $9929.2 in Q4 2023, and $1266.7 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 21.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,283.50 |
| Dec 31, 2024 | -1,283.50 |
| Dec 31, 2023 | 9,929.22 |
| Dec 31, 2023 | 9,929.22 |
| Sep 30, 2023 | 1,266.68 |
| Sep 30, 2023 | 1,266.68 |
| Dec 31, 2021 | 144,237.13 |
| Dec 31, 2021 | 144,237.13 |
| Sep 30, 2021 | -8,271.50 |
| Sep 30, 2021 | -8,271.50 |
| Jun 30, 2021 | -46,125.03 |
| Jun 30, 2021 | -46,125.03 |
| Mar 31, 2021 | -5,515.68 |
| Mar 31, 2021 | -5,515.68 |
| Dec 31, 2020 | 938,840.66 |
| Dec 31, 2020 | 938,840.66 |
| Sep 30, 2020 | -433,608.93 |
| Sep 30, 2020 | -433,608.93 |
| Jun 30, 2020 | -4,966.78 |
| Jun 30, 2020 | -4,966.78 |